Hong Kong
· Delayed Price · Currency is HKD Sirnaomics Company Description
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs.
The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections.
Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.
The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases.
In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension.
The company was founded in 2007 and is based in Wan Chai, Hong Kong.
| Country | Cayman Islands |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Hung Fai Poon |
Contact Details
Address: Hopewell Centre Wan Chai Hong Kong | |
| Website | sirnaomics.com |
Stock Details
| Ticker Symbol | 2257 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG2050P1028 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hung Fai Poon Ph.D. | Chief Executive Officer and Executive Director |
| Dr. Yang Lu Ph.D. | Honorary Scientific Scientific Officer |
| Dr. David Mark Evans Ph.D. | Head of Drug Discovery and Collaboration |
| Dr. Yongxiang Wang | Chief Production Officer |
| Yun Ting Yuen | Company Secretary |